Cite
HARVARD Citation
Devaux, A. et al. (n.d.). 281TiPA phase Ib/II study of durvalumab combined with dose-dense EC in neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers (B-IMMUNE). Annals of oncology. p. . [Online].